EP
DSGN icon

Essential Partners’s Design Therapeutics DSGN Stock Holding History

Essential Partners’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14 Hold
1
– – ﹤0.01% 2840
2026
Q1 		$11 Buy
+1
New +$10 ﹤0.01% 2836

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Essential Partners's DSGN Position: Q2 2026 in Review

Essential Partners held its Design Therapeutics (DSGN) position steady in Q2 2026 at 1 share worth $14. The position accounts for ﹤0.01% of the portfolio, ranked #2840.

Essential Partners first reported a position in DSGN in Q1 2026 and has held it in 2 quarters since. 137 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • Essential Partners held 1 share of Design Therapeutics worth $14 as of Q2 2026.
  • Essential Partners left its Design Therapeutics share count unchanged in Q2 2026.
  • Design Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2840 holding.
  • Essential Partners first reported a position in Design Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 137 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.